Better Therapeutics(BTTX)
$0.00+0.00 (+9900.00%)
BTTX
Better Therapeutics financials statements
$0.00
At close:+0.00 (+9900.00%)
Better Therapeutics (BTTX) Ratios
168 Followers
Better Therapeutics Ratios
BTTX's free cash flow for Q3 2023 was $-5.95M. For the 2023 fiscal year, BTTX's free cash flow was decreased by $-5.00K and operating cash flow was $-5.94M. See a summary of the company’s cash flow.
| Ratios | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|
| Liquidity Ratios | ||||
| Current Ratio | 1.37 | 9.56 | 0.76 | 2.03 |
| Quick Ratio | 1.37 | 9.56 | 0.76 | 2.03 |
| Cash Ratio | 1.17 | 8.57 | 0.20 | 1.56 |
| Solvency Ratio | -1.67 | -2.72 | -0.48 | -1.04 |
| Operating Cash Flow Ratio | -2.14 | -6.51 | -9.42 | -12.79 |
| Short-Term Operating Cash Flow Coverage | -6.38 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -5.40M | $ 31.01M | $ -12.68M | $ -4.50M |
| Leverage Ratios | ||||
| Debt-to-Assets Ratio | 0.65 | 0.19 | 0.10 | 1.02 |
| Debt-to-Equity Ratio | -16.55 | 0.26 | -0.09 | -8.26 |
| Debt-to-Capital Ratio | 1.06 | 0.21 | -0.10 | 1.14 |
| Long-Term Debt-to-Capital Ratio | 1.10 | 0.21 | -0.10 | 1.14 |
| Financial Leverage Ratio | -25.52 | 1.39 | -0.95 | -8.07 |
| Debt Service Coverage Ratio | -6.35 | -208.28 | -62.12 | -518.27 |
| Interest Coverage Ratio | -25.66 | -165.19 | -63.23 | -524.82 |
| Debt to Market Cap | 0.57 | 0.09 | 0.01 | 0.02 |
| Interest Debt Per Share | 0.69 | 0.41 | 0.10 | 0.21 |
| Net Debt to EBITDA | 0.02 | 0.80 | -0.09 | -0.74 |
| Profitability Margins | ||||
| Gross Profit Margin | 0.00% | 0.00% | -8425.00% | -4888.89% |
| EBIT Margin | 0.00% | 0.00% | -76675.00% | -32072.22% |
| EBITDA Margin | 0.00% | 0.00% | -75737.50% | -31672.22% |
| Operating Profit Margin | 0.00% | 0.00% | -79037.50% | -32072.22% |
| Pretax Profit Margin | 0.00% | 0.00% | -77925.00% | -32133.33% |
| Net Profit Margin | 0.00% | 0.00% | -79837.50% | -32194.44% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -79837.50% | -32133.33% |
| Net Income Per EBT | 100.02% | 99.62% | 102.45% | 100.19% |
| EBT Per EBIT | 103.90% | 132.49% | 98.59% | 100.19% |
| Return on Assets (ROA) | -173.30% | -79.15% | -100.00% | -118.73% |
| Return on Equity (ROE) | 4422.69% | -109.84% | 94.51% | 957.85% |
| Return on Capital Employed (ROCE) | -404.93% | -66.11% | -109.51% | -131.35% |
| Return on Invested Capital (ROIC) | -273.67% | -65.86% | -109.51% | -131.35% |
| Return on Tangible Assets | -208.66% | -87.91% | -767.67% | -359.05% |
| Earnings Yield | -152.06% | -36.75% | -8.45% | -2.46% |
| Efficiency Ratios | ||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.90 | 1.06 | 1.33 | 2.68 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.09 | 0.10 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.05 | 0.00 |
| Cash Conversion Cycle | -405.93 | -343.36 | -275.09 | -136.16 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 405.93 | 343.36 | 275.09 | 136.16 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | ||||
| Operating Cash Flow Per Share | -1.23 | -1.31 | -0.76 | -0.26 |
| Free Cash Flow Per Share | -1.28 | -1.35 | -1.07 | -0.38 |
| Dividend Paid and CapEx Coverage Ratio | -24.52 | -28.77 | -2.50 | -2.27 |
| Capital Expenditure Coverage Ratio | -24.52 | -28.77 | -2.50 | -2.27 |
| Operating Cash Flow Coverage Ratio | -1.94 | -3.24 | -9.02 | -1.24 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -721.75 | -345.39 |
| Free Cash Flow Yield | -115.15% | -29.06% | -10.69% | -3.79% |
| Valuation Ratios | ||||
| Price-to-Earnings (P/E) Ratio | -0.66 | -2.72 | -11.83 | -40.72 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 9446.88 | 13110.95 |
| Price-to-Book (P/B) Ratio | -29.09 | 2.99 | -11.18 | -390.08 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.87 | -3.44 | -9.35 | -26.36 |
| Price-to-Operating Cash Flow Ratio | -0.90 | -3.56 | -13.09 | -37.96 |
| Price-to-Earnings Growth (PEG) Ratio | 0.56 | -0.04 | -0.04 | 0.00 |
| Enterprise Value Multiple | -0.66 | -2.03 | -12.56 | -42.14 |
| Enterprise Value | 25.29M | 78.69M | 76.09M | 240.24M |
| EV to EBITDA | -0.66 | -2.03 | -12.56 | -42.14 |
| EV to Sales | 0.00 | 0.00 | 9511.50 | 13346.68 |
| EV to Free Cash Flow | -0.84 | -2.47 | -9.42 | -26.83 |
| EV to Operating Cash Flow | -0.87 | -2.55 | -13.18 | -38.64 |
| Tangible Book Value Per Share | -0.20 | 1.34 | -1.63 | -0.16 |
| Shareholders’ Equity Per Share | -0.04 | 1.56 | -0.89 | -0.03 |
| Tax and Other Ratios | ||||
| Effective Tax Rate | -0.00 | 0.00 | -0.02 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.69 | -1.71 | -0.85 | -0.25 |
| Tax Burden | 1.00 | 1.00 | 1.02 | 1.00 |
| Interest Burden | 1.04 | 1.00 | 1.02 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 372.25 | 127.22 |
| SG&A to Revenue | 0.00 | 0.00 | 306.88 | 122.06 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 29.13 | 4.67 |
| Income Quality | 0.73 | 0.76 | 0.90 | 1.07 |
Currency in USD
